HomeESPR • NASDAQ
add
Esperion Therapeutics Inc
Previous close
$0.78
Day range
$0.75 - $0.81
Year range
$0.69 - $3.94
Market cap
158.35M USD
Avg Volume
6.41M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 65.00M | -52.81% |
Operating expense | 43.00M | 2.40% |
Net income | -40.46M | -166.30% |
Net profit margin | -62.24 | -240.50% |
Earnings per share | -0.21 | -161.76% |
EBITDA | -22.07M | -130.52% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 114.63M | -49.41% |
Total assets | 324.03M | -13.14% |
Total liabilities | 750.24M | 12.42% |
Total equity | -426.21M | — |
Shares outstanding | 198.20M | — |
Price to book | -0.36 | — |
Return on assets | -16.54% | — |
Return on capital | -29.84% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -40.46M | -166.30% |
Cash from operations | -22.63M | -142.04% |
Cash from investing | — | — |
Cash from financing | -7.50M | -108.28% |
Net change in cash | -30.13M | -120.87% |
Free cash flow | -18.77M | -201.63% |
About
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Wikipedia
Founded
May 1998
Website
Employees
304
